Pioglitazone, Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Non diabetic patients on renal replacement therapy are prone to changes in body composition
with an increase in visceral fat and muscle wasting all favoured by the insulin resistant
state. Malnutrition is associated with a worst prognosis in these patients. Glitazones are
the most powerful insulin sensitisers available in clinical practice which also have
anti-inflammatory properties. Their use has been associated with significant and favourable
changes in body fat distribution in type 2 diabetic subjects. Experimental studies suggest
that glitazones may attenuate muscle wasting in renal failure.
The goal of this study was to examine in non diabetic ESRD patients the effects of
pioglitazone on inulin sensitivity and protein metabolism as determined by the
hyperinsulinemic euglycemic clamp and on changes in body composition as determined by
anthropometric measurements, dual energy X-ray absorptiometry (DEXA) and CT-scan determined
changes in abdominal visceral and sub-cutaneous fat.